Function interactions between mitogen-activated protein kinases (MAPKs) and SARS-CoV-2
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 5R01AI170596-03
Grant search
Key facts
Disease
COVID-19Start & end year
20232028Known Financial Commitments (USD)
$827,164Funder
National Institutes of Health (NIH)Principal Investigator
ASSOCIATE PROFESSOR Jeffrey JohnsonResearch Location
United States of AmericaLead Research Institution
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen genomics, mutations and adaptations
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
PROJECT SUMMARY SARS-CoV-2, the causative agent of the COVID-19 pandemic, modifies the cells that it infects in profound ways. One such modification is the activation of host cellular mitogen-activated protein kinase (MAPK) pathways, which contribute to severe inflammation that is a hallmark of severe COVID-19 disease. Inhibition of one MAPK pathway, the p38/MAPK pathway, reduces SARS-CoV-2 replication by an undefined mechanism. This proposal aims to measure the impact of human MAPK pathways on SARS-CoV-2 infection using a multidisciplinary approach that combines state-of-the-art proteomics technologies, medium-throughput genetic screening, and in vivo and ex vivo models of SARS-CoV-2 infection. These findings will inform the potential application of MAPK inhibitors for COVID-19 treatment and may identify alternative targets within the MAPK families. MAPK pathways play critical roles in many disease states, and this work will inform research in these areas by providing molecular mechanisms for MAPK regulation and providing tools for the unbiased discovery of MAPK substrates and regulators.